North Dallas Bank & Trust Co. Invests $593,000 in Medtronic PLC $MDT

North Dallas Bank & Trust Co. acquired a new position in Medtronic PLC (NYSE:MDT) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,172 shares of the medical technology company’s stock, valued at approximately $593,000.

A number of other institutional investors and hedge funds have also modified their holdings of MDT. Brighton Jones LLC lifted its stake in shares of Medtronic by 1,368.0% in the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after buying an additional 37,265 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Medtronic by 9.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock valued at $380,000 after purchasing an additional 381 shares during the last quarter. Jump Financial LLC acquired a new position in Medtronic during the 2nd quarter valued at $299,000. Main Street Financial Solutions LLC raised its stake in Medtronic by 28.9% during the 2nd quarter. Main Street Financial Solutions LLC now owns 14,356 shares of the medical technology company’s stock valued at $1,251,000 after purchasing an additional 3,218 shares during the last quarter. Finally, HUB Investment Partners LLC raised its stake in Medtronic by 21.3% during the 2nd quarter. HUB Investment Partners LLC now owns 19,226 shares of the medical technology company’s stock valued at $1,676,000 after purchasing an additional 3,376 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on MDT shares. Rothschild & Co Redburn cut their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. UBS Group cut their target price on shares of Medtronic from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Leerink Partners cut their target price on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. BTIG Research upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and set a $90.00 target price for the company in a research note on Wednesday, June 3rd. Finally, Piper Sandler cut their target price on shares of Medtronic from $91.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Seventeen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $99.00.

Medtronic Trading Up 1.5%

Shares of MDT stock opened at $81.93 on Wednesday. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33. The stock has a market cap of $105.19 billion, a price-to-earnings ratio of 21.96, a P/E/G ratio of 1.96 and a beta of 0.58. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The firm has a fifty day moving average of $81.21 and a 200-day moving average of $91.74.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.61%. The company had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the prior year, the company posted $1.62 EPS. The business’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 17th. Stockholders of record on Friday, June 26th will be paid a $0.72 dividend. The ex-dividend date is Friday, June 26th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio is currently 76.14%.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Healthcare is outperforming as investors rotate away from tech, which supports Medtronic as a defensive name in a stronger sector. As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
• Positive Sentiment: Medtronic won FDA clearance for its updated Nellcor pulse oximetry system, a technology update aimed at improving reliability across diverse patients and care settings. Medtronic gets FDA nod for updated pulse oximetry system
• Positive Sentiment: The company earned CE mark approval for its Stealth AXiS robot platform in ENT surgery, opening the door to broader use in Europe. Medtronic earns CE mark for Stealth AXiS robot platform in ENT surgery
• Positive Sentiment: Medtronic also received FDA clearance for an upgraded Nellcor pulse oximetry system with an intelligent processor, reinforcing momentum in its monitoring portfolio. Medtronic wins FDA clearance for Nellcor pulse oximetry system with intelligent processor
• Positive Sentiment: Analyst commentary has been increasingly constructive, with some writers arguing Medtronic may be one of the better buys in healthcare after its recent results showed solid growth. Why Medtronic Stock May Have Just Become the Best Buy in the Entire Healthcare Sector
• Neutral Sentiment: Medtronic’s EVP Harry Skip Kiil sold 4,189 shares, a routine insider transaction that may modestly weigh on sentiment but does not by itself signal a major change in outlook. Harry Skip Kiil insider transaction
• Neutral Sentiment: MarketWatch noted the stock underperformed some peers despite gains, suggesting investors are still comparing Medtronic’s move against stronger healthcare competitors. Medtronic PLC stock underperforms Tuesday when compared to competitors despite daily gains

Insider Activity

In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).